Clinical Pharmacogenomics of Antidepressant Response
Status:
Unknown status
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The study includes two components：(1) cross-sectional (Study I), and (2) longitudinal
treatment trial (Study II). The cross-sectional component will include all subjects initially
recruited for the parent project. Genotyping characteristics will be compared with clinical
status (i.e., recovered vs symptomatic). The treatment trial component (one) will include a
subset of the subjects (n = 400) who remain significantly depressed. They will be randomly
assigned to 8-weeks of treatment with either citalopram or paroxetine. With such a design, we
wish to test the following hypotheses：
Ⅰ. Depressed patients with the short variant of the serotonin transporter (5HTTLPR) will
respond faster and better to antidepressants compared to their counterparts with the long
variant. Concurrently, patients with the 5-HTT Stin2 12/12 allele will also show better
response as compared to those with the 10/12 allele.
Ⅱ. Depressed patients who are homozygous for deficient or less active CYP2D6 or CYP2C19
enzyme(s) will be more likely to show treatment emergent side effects compared to subjects
with the wildtype alleles. Specifically, in Study II, CYP2D6 polymorphism will predict PAR
but not CIT side effects and CYP2C19 polymorphism will be associated with CIT but not PAR
side effects.
Phase:
Phase 4
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital Jing-Ho Mental Hospital, Taiwan National Science Council, Taiwan Taipei Medical University WanFang Hospital Tsyr-Huey Mental Hospital